Chiara Cremolini
0000-0002-0520-4841
310 papers found
Refreshing results…
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis
Zebrafish Patient Derived Xenograft Model of Colon Cancer as Personalized Medicine Tool to Predict the Most Effective Treatment Strategy
Disease characteristics in younger patients with colorectal cancer
Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis
Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD Study
Clinical applications of bevacizumab in the treatment of colorectal and ovarian cancer,Applicazioni cliniche di bevacizumab nel trattamento del tumore del colon-retto e dell’ovaio
Clinical applications of bevacizumab in the treatment of colorectal and ovarian cancer
Considerations in the management of younger patients with colorectal cancer
Treatments after first progression in metastatic colorectal cancer. A literature review and evidence-based algorithm
Clinical validation of a machine-learning derived signature predictive of outcomes from first-line oxaliplatin-based chemotherapy in advanced colorectal cancer
Universal Pretreatment DPYD Genotyping in Fluoropyrimidine Candidates: Still Controversial but With Clear Instructions for Practitioners, at Last!
Oligometastatic colorectal cancer: prognosis, role of locoregional treatments and impact of first-line chemotherapy—a pooled analysis of TRIBE and TRIBE2 studies by Gruppo Oncologico del Nord Ovest
Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer
Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients
Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO
Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer
A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer
Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis
Missing publications? Search for publications with a matching author name.